Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

Video

Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.

Related Videos
A panel of 4 experts on MDS
A panel of 4 experts on MDS
A panel of 6 experts on follicular lymphoma and mantle cell lymphoma seated at a long desk
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
Pooja Advani, MBBS, MD, Mayo Clinic